Sep. 8, 2009 (PR Newswire) -- EAST BRUNSWICK, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that five abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will be presented at the 2009 ACR/ARHP Annual Scientific Meeting taking place in Philadelphia from October 16-21, 2009. The posters will be presented during the "Treatment and Outcome" session on October 19, 2009 and include:
-- Chronic Use of Pegloticase: Safety and Efficacy Update (Abstract # 1113)
- October 19, 2009 at 9:00 a.m. Eastern Time
-- First Application of Computer-Assisted Analysis of Digital Photographs
for Assessing Tophus Response: Phase 3 Studies of Pegloticase in
Treatment Failure Gout (Abstract # 1111) - October 19, 2009 at 9:00 a.m.
Eastern Time
-- Improvement in Health-Related Quality of Life (HRQOL) in Patients with
Treatment Failure Gout (TFG) Treated with Pegloticase Measured by SF-6D
Derived Utility (Abstract # 1101) - October 19, 2009 at 9:00 a.m.
Eastern Time
-- Routine Serum Uric Acid (SUA) Monitoring Predicts Antibody-Mediated Loss
of Response and Infusion Reaction Risk during Pegloticase Therapy
(Abstract # 1104) - October 19, 2009 at 9:00 a.m. Eastern Time
-- The Costs of Treatment Failure Gout: A Claims-Based Analysis (Abstract #
1112) - October 19, 2009 at 9:00 a.m. Eastern Time
For complete information on all five abstracts, please visit the American College of Rheumatology website at www.rheumatology.org.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com.
